Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 65162-724

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 65162-724). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Rabeprazole Sodium Delayed Release Tablets 1)

Chemical structure of rabeprazole sodium illustrated as a molecular diagram with rings and functional groups representative of the compound.*

FDA Label Image

1 (Rabeprazole Sodium Delayed Release Tablets 2)

Line graph titled 'Mean Daytime Heartburn Scores RAB-USA-2' showing mean heartburn scores over 28 study days for placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). Scores decrease for Rabeprazole groups after day 0 indicating reduced heartburn severity compared to placebo.*

FDA Label Image

1 (Rabeprazole Sodium Delayed Release Tablets 3)

A line chart titled 'Mean Nighttime Heartburn Scores RAB-USA-2' showing mean heartburn scores over study days from -14 to 28. It compares three groups: Placebo (n=68), Rabeprazole 10 mg (n=64), and Rabeprazole 20 mg (n=67). The y-axis shows mean score ranging from 0 (None) to 4 (Very Severe). Scores decrease after day 0 across all groups with some variation between the treatments over time.*

FDA Label Image

1 (Rabeprazole Sodium Delayed Release Tablets 4)

A line graph titled 'Mean Daytime Heartburn Scores RAB-USA-3,' showing mean heartburn scores over days in a study comparing placebo and Rabeprazole 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis represents mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph depicts lower heartburn scores in the Rabeprazole 20 mg group after day 0 compared to placebo.*

FDA Label Image

1 (Rabeprazole Sodium Delayed Release Tablets 5)

A line chart titled 'Mean Nighttime Heartburn Scores RAB-USA-3' comparing placebo and Rabeprazole 20 mg groups over a 28-day study period. The vertical axis shows mean heartburn scores from 0 (None) to 4 (Very Severe). Two lines represent mean scores for placebo (n=58) and Rabeprazole 20 mg (n=59). Scores decrease after day 0, with the Rabeprazole group showing consistently lower scores than placebo.*

FDA Label Image

10 (Rabeprazole Sodium Delayed Release Tablets 6)

Label for Rabeprazole Sodium Delayed-release Tablets 20 mg by Amneal Pharmaceuticals LLC. The label shows a description of 20 mg dosage strength, 30 tablets per container, with dosing and storage instructions. It includes the NDC 65162-724, a QR code for the medication guide, and manufacturer and distributor information for Amneal Pharmaceuticals Pvt. Ltd. and Amneal Pharmaceuticals LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.